Two years after Peloton Therapeutics was acquired by Merck & Co. Inc. (NYSE: MRK), Peloton CEO John A. Josey is leading a new startup called Atavistik Bio, based on technology out of the Howard Hughes Medical Institute and the University of Texas Southwestern Medical Center.

Josey is acting CEO of the Cambridge-based company, having led a $60 million Series A investment through The Column Group, the venture capital firm where he is now a venture partner. He is working closely with chief scientific…

Boston Biz Journal https://www.bizjournals.com/boston/news/2021/08/24/ex-peloton-ceo-atavistik-bio-launch-60m.html?ana=RSS&s=article_search